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Following publication of the original article \[[@CR1]\], the author reported the wrong version of Figs. [5](#Fig1){ref-type="fig"} and [7](#Fig2){ref-type="fig"} have been published. The correct version of the figures can be found below:Fig. 5Monomeric soluble DLL1 or *Dll1*-ablated dendritic cells restrict Notch signaling and impair T-cell cytotoxic responses. **a** Expression of Notch downstream target *Hes1* mRNA was assessed by qRT-PCR in 3 T3 cells treated with clustered DLL1 in the presence of soluble DLL1 (sDLL1) construct at indicated concentrations for 16 h. **b**, **c** T-cell proliferation was measured after co-incubating allogeneic T-cells labeled with Cell Tracer Violet fluorescent dye with bone marrow-derived *Dll1*^*−/−*^ or wild-type DC in the presence of soluble anti-CD3 for 5 days. In some T-cell cultures with wild-type DC, soluble DLL1 construct was added at the indicated concentrations. Representative Cell Tracer Violet dye dilution profile is shown (**b**). **d** Tumor volume was measured in LLC tumor-bearing mice treated with sDLL1 construct 1 mg/kg body weight, i.p. every 2 days for 20 days. **e** IFN-γ producing tumor-infiltrating cells from these mice were enumerated by ELISPOT assay on day 18 after LLC tumor initiation. Mean ± SEM, 8 mice per group; \*, *p* \< 0.05; \*\*, *p* \< 0.005. **f**, **g** C57BL/6 mice were transplanted with BALB/c heart allografts on day 0 and treated with sDLL1 construct (1 mg/kg) i.p. on days − 3, − 1, 1, 3, 5 and 7. **f** Heart allografted C57BL/6 mice log-rank survival. **g** IFN-γ ELISPOT assay on recipient CD8^+^T cells isolated after heart allograft and re-stimulated with mitomycin C-treated donor spleen cells in the presence of recipient C57BL/6 splenocytes. **h** Percentage of FoxP3^+^ cells among CD4^+^ splenocytes after heart allograft. Mean ± SEM, 4--8 mice per group; \*, *p* \< 0.05Fig. 7Dendritic cell Jagged expression correlates with PD-1 expression on T-effector-memory cells. **a** Purified T cells were stimulated in vitro in a T:DC (3:1) stimulation co-culture with allogeneic bone marrow-derived dendritic cells in the presence of CD3/CD28 beads (1 μg/mL) for four days with or without treatment with clustered DLL1 (1.5 μg/mL) or monovalent soluble JAG1 (20 μg/mL) constructs. Expression of CD62L, CD44, CTLA-4 and PD-1 was assessed on gated populations as indicated by flow cytometry. Dot plots from a representative experiment out of two independent experiments with duplicates are shown. **b**-**c** Lung tumor single cell suspensions from 10 patients were evaluated for the expression of NOTCH ligands on tissue-resident CD11b^+^CD11c^high^ dendritic cells and PD-1 and NOTCH receptors in populations of T cells by flow cytometry. NOTCH ligands in CD11b^+^CD11c^high^ cells were compared to PD-1 positivity of Tem and Tcm cells (**b**) or to NOTCH receptor positive T cell subsets by Pearson's correlation (**c**). All *p*-values were corrected using the Benjamani- Hochberg procedure; *n* = 8; \* *p* \< 0.05. Color code indicates the strength of correlation. **d** Scheme summarizing available data on the regulation of T cell responses by Notch ligands

The original article has been corrected as well.
